Strive increased its bitcoin treasury to 36,818 BTC after buying 1,223 BTC last week, completing a total weekly purchase of 4,045 BTC at an average price around $82,000. The company also exercised warrants, raising about $369 million and increasing its Class A shares. Strive is set to settle a $700 million preferred stock offering called SATS on October 20, which includes a 15% dividend and a reserve for the first 18 months of payments. Proceeds from this offering may be used for further bitcoin purchases and general corporate purposes, signaling continued growth in Strive's bitcoin holdings and financial flexibility.
Strive's bitcoin holdings provide context for cryptocurrency market trends. For readers following crypto, here is Pluang's market snapshot as of Oct 19, 2026 20:22 WIB: 31 of 50 major cryptocurrencies rose today, 18 fell. Notable movers include BAT at Rp3.255 with a 2.03% increase and 93% buy order activity, FTM at Rp11.382 down 2.05%, and ENJ at Rp488 down 1.94% with 95% sell order activity.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
